Catalyst Pharmaceuticals Receives Breakthrough Therapy Designation

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), focused on developing prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, today announced that its investigational product Firdapse(TM) (amifampridine phosphate) has received “Breakthrough Therapy Designation” by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). 

As quoted in the press release:

“We are very pleased to have received Breakthrough Therapy Designation for Firdapse(TM) and we are excited by the FDA’s decision to place our product in a category that may enable expedited development and review for patients with LEMS,” said Patrick McEnany, President and Chief Executive Officer of Catalyst. “With no approved or effective symptomatic treatment currently available for LEMS, Firdapse(TM) has the potential to be the first-line treatment option for patients with this rare condition.”

Click here for the full press release from Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)